Chugai Pharmaceutical (OTCMKTS:CHGCY) Shares Down 4.8% - Here's Why

Key Points

• Chugai Pharmaceutical's shares fell by 4.8%, closing at $23.14, after trading as low as $22.12 on a day with a 20% drop in trading volume compared to average levels.
• The company reported quarterly earnings of $0.20 per share, with a revenue of $2.01 billion and a return on equity of 20.80%.
• Chugai Pharmaceutical has a market capitalization of $76.09 billion and is involved in the development of various oncology-related pharmaceuticals.

Shares of Chugai Pharmaceutical Co., Ltd. Unsponsored ADR (OTCMKTS:CHGCY - Get Free Report) dropped 4.8% during mid-day trading on Tuesday . The company traded as low as $22.12 and last traded at $23.14. Approximately 161,825 shares traded hands during trading, a decline of 20% from the average daily volume of 202,307 shares. The stock had previously closed at $24.30.

Chugai Pharmaceutical Trading Down 4.9%

The firm has a market capitalization of $76.09 billion, a PE ratio of 29.27 and a beta of 0.64. The business has a 50 day moving average price of $22.48 and a 200-day moving average price of $24.43.

Chugai Pharmaceutical (OTCMKTS:CHGCY - Get Free Report) last released its quarterly earnings data on Thursday, July 24th. The company reported $0.20 earnings per share for the quarter. Chugai Pharmaceutical had a return on equity of 20.80% and a net margin of 33.08%.The firm had revenue of $2.01 billion during the quarter. On average, equities research analysts forecast that Chugai Pharmaceutical Co., Ltd. Unsponsored ADR will post 0.74 earnings per share for the current year.

Chugai Pharmaceutical Company Profile

Chugai Pharmaceutical Co, Ltd., together with its subsidiaries, engages in the research, development, manufacture, sale, importation, and exportation of pharmaceuticals in Japan and internationally. The company's products for oncology primarily include Avastin, FoundationOne, Polivy, Rozlytrek, Tecentriq, Perjeta, Alecensa, Herceptin, Kadcyla, Rituxan, and Gazyva; Edirol, an Osteoporosis agent; Mircera, an erythropoiesis agent; Oxarol, an agent for secondary hyperparathyroidism; and other diseases comprise Hemlibra, CellCept, Bonviva, Tamiflu, Evrysdi, Ronapreve, Vabysmo, and Enspryng.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.